
Laurus Labs shares jumped 128% from their March low to ₹2,087, delivering the biggest rally in the company's history after reporting strong Q2FY27 results that surpassed market expectations. The stock gained 1% intraday and closed near its all-time high, with the broader pharma sector rallying in tandem. According to reports from Business Standard, the stock outperformed significantly across multiple timeframes, with 6% gains in the past month compared to a 1% decline in the BSE Sensex. In the past three months, Laurus Labs' market price rallied 35%, while the benchmark index declined 4.7%. The stock has soared 83% in the past six months, against a 5% fall in the BSE Sensex. The rally lifted the Nifty Pharma index by 0.8% during the session, with other pharma names also seeing gains as the positive sentiment boosted investor confidence in the Indian pharma sector.
The company's Q2FY27 EBITDA grew 67% year-on-year to ₹680 crore, significantly exceeding market expectations and driving the stock's historic rally. As per Business Standard, analysts at Kotak Institutional Equities had projected EBITDA growth of 67% YoY to ₹680 crore with EBITDA margin expansion of 680 bps to 31.2%. The margin expansion to 31.2% further underlined the company's operational efficiency and improved cost management, with analysts expecting gross margins to improve by 240 bps YoY to 62.3%. The strong earnings outlook was driven by the company's robust growth trajectory and successful navigation of competitive markets while maintaining cost discipline. The company has been expanding its product portfolio and gaining market share in the high-margin specialty drugs segment, with the EBITDA growth reflecting both volume growth and pricing power.
The Contract Development and Manufacturing Organization (CDMO) sector continues to demonstrate strong momentum, with India Ratings and Research reporting double-digit revenue growth in Q1FY27 despite temporary headwinds from customer destocking and product attrition. As reported by Business Standard, the Indian CDMO segment, currently generating revenue of $3-3.5 billion, is expected to rise by seven times to about $22-25 billion by 2035. This growth is driven by rising outsourcing and supply chain rebalancing initiatives by global pharmaceutical and biotech companies. The CDMO sector reported another quarter of double-digit revenue growth in the first quarter of financial year FY27 (Q1FY27) on a year-on-year basis, highlighting the continued strength of underlying demand. The runway for Indian CDMO players remains strong as the segment, which currently accounts for about 2-3 per cent of global CDMO revenue of $140-145 billion, is expected to rise by seven times to about $22-25 billion by 2035, according to InCred Research.
According to reports from Business Standard, Laurus Labs is scheduled to announce its Q2FY27 results on October 29, 2026, with the board of directors' meeting to consider and approve un-audited financial results for the quarter and half-year ended September 30, 2026, and the payment of interim dividend for FY 2026-27. The company operates as a research-driven pharmaceutical and biotechnology company with leadership positions in developing and manufacturing Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms across anti-retroviral, oncology, cardiovascular, and gastro therapeutics sectors. Last week, Laurus Labs informed BSE that the board of directors' meeting is scheduled for October 29, 2026, to consider and approve the un-audited financial results for the quarter and half-year ended September 30, 2026, and the payment of interim dividend for FY 2026-27.